Schall Firm Logo 2.jpg
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against BeiGene, Ltd. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
September 25, 2019 09:55 ET | Schall Law
LOS ANGELES, Sept. 25, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 18, 2019 10:50 ET | Schall Law
LOS ANGELES, Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 13, 2019 17:06 ET | Schall Law
LOS ANGELES, Sept. 13, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
September 11, 2019 16:30 ET | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update
September 08, 2019 01:01 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019 08:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 03, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma
August 21, 2019 16:30 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 21, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports Second Quarter 2019 Financial Results
August 08, 2019 16:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
July 07, 2019 20:00 ET | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)
June 20, 2019 11:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 20, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...